Find policies, billing codes, payers, states, and providers
Diabetic Neuropathy: Selected Treatments
Customize your policy alerts
Sign up for Aetna Policy 0729 alerts
Get alerted when Policy 0729 changes without checking for updates manually.
Monitor payer policy activity
This bulletin describes Aetna's coverage stance for select interventions used to treat diabetic neuropathy, specifying which treatments are medically necessary, not medically necessary, or considered experimental/investigational, and lists related coding. It applies to Aetna members and providers managing diabetic neuropathy treatment decisions.
No material clinical or coverage changes in this revision.
Coverage Criteria for Selected Treatments
Medically necessary interventions
Aetna considers the following interventions medically necessary:
Use beyond 4 weeks is considered not medically necessary.
Experimental and investigational interventions (selected list)
Aetna considers the following interventions experimental and investigational because their clinical value for this indication has not been established:
Surgical decompression may be considered medically necessary for entrapment syndromes even when diabetic neuropathy is present (see footnote).
Pharmacologic therapy
Covered when supported by guideline-level evidence and after appropriate trial of first-line therapies:
Guidelines (AAN and others) state pregabalin is Level A; several other agents are Level B.
Interventional, device-based, and investigational therapies
Use of invasive, device-based, or investigational therapies may be considered only with documented failure of guideline-recommended therapies and explicit informed consent regarding limited evidence and risks:
Cochrane review failed to identify well-designed RCT evidence; surgical decompression may be considered for entrapment syndromes per policy footnote.
Consider short trial per guideline recommendations (3–4 weeks for electrical stimulation).
Require caution and close monitoring; use generally limited to clinical trials or exceptional circumstances.
Considered investigational or adjunctive pending further evidence.
Insufficient / Not Supported Treatments
Not supported by adequate evidence or considered experimental:
Not supported for PDN.
Evidence insufficient for routine coverage.
Insufficient evidence to support routine use.
SCS (including 10-kHz) — candidate criteria
Spinal cord stimulation (SCS) for refractory PDPN — candidate requirements drawn from clinical trials (e.g., SENZA‑PDN):
Eligibility criteria reflect populations studied in randomized trials such as SENZA‑PDN; document trial outcome and prior treatments.
Ozone therapy — coverage-relevant evidence
Ozone therapy for diabetic foot ulcers — evidence summary:
Methodological limitations and small sample sizes limit confidence in effect estimates.
MIRE — evidence
Monochromatic infrared phototherapy (MIRE) — evidence summary:
Not established as effective for neuropathic pain.
Plantar electrical stimulation — evidence
Plantar electrical‑stimulation — evidence from a single small randomized trial:
Preliminary positive signals but insufficient for routine coverage.
Biologic and regenerative therapies — investigational
Other investigational biologic and regenerative approaches — coverage‑relevant summary:
Examples: small ghrelin infusion study (n=7) reported motor NCV improvement; autologous BMMNC single‑arm series (n=168) reported symptomatic and NCS improvements but lacked control groups.
Evidence summaries and investigational stance
Summary of coverage‑relevant evidence and investigational signals:
Generally considered investigational without RCT data.
Considered investigational except possibly in select refractory cases with prior authorization and documented prior therapy failure.
Evidence mixed; may be considered as adjunct after first‑line failure.
Generally investigational; document informed consent and consider trial enrollment if used clinically.
Consideration for ALA trial
Consideration for a trial of alpha‑lipoic acid (ALA):
Recommendation sourced from UpToDate; systematic review evidence is inconsistent.
Surgical decompression for diabetic neuropathy is categorized as experimental and investigational in this policy because its effectiveness for diabetic symmetric distal polyneuropathy has not been established. The policy notes a footnote that decompression may be considered medically necessary when performed for entrapment syndromes even if diabetic neuropathy is present, but routine decompressive surgery for diffuse diabetic neuropathy lacks sufficient evidence to be considered established.
The policy highlights the absence of well‑designed randomized controlled trials demonstrating benefit for decompressive surgery in diabetic symmetric distal polyneuropathy; a Cochrane-style review identified no RCT showing improvements in predefined endpoints. In addition, a randomized, double‑blind trial of topical 5% ketamine (n=17) found no treatment benefit versus placebo, supporting the policy position that topical ketamine is not effective for diabetic neuropathic pain and is considered not supported by evidence.
Multiple therapies are listed as experimental or investigational due to limited, inconsistent, or low‑quality evidence. Examples called out in the policy include ozone therapy for diabetic foot ulcers (Cochrane review: small RCTs with high/unclear bias), monochromatic infrared phototherapy (MIRE) with inconsistent and low‑quality trial results, and a range of biologic and autologous bone marrow–derived stem cell approaches that have promise in preclinical models or small human series but lack randomized controlled trial evidence to support routine coverage.
The policy identifies several interventions that are supported only by uncontrolled pre‑post data, small single‑arm cohorts, or very small case series and therefore remain investigational. For example, an uncontrolled intramuscular autologous BMMNC cohort (n=168) reported symptomatic and nerve‑conduction improvements without a control group; similarly, many stem‑cell and early biologic reports derive from preclinical or pilot human work and are insufficient to establish clinical effectiveness.
The policy excerpts do not specify explicit exclusion criteria for alpha‑lipoic acid (ALA). ALA is discussed in evidence summaries as having inconsistent RCT results and is described as a possible adjunct in some guidance sources, but no formal exclusions or prior authorization triggers for ALA are provided in the cited sections.
Percutaneous electrical stimulation is covered only as a short‑term therapeutic option after failure of conventional medical treatments, and the policy explicitly states that use beyond 4 weeks is considered not medically necessary.
The policy groups together treatments that have shown no benefit in randomized trials or are supported only by weak or inconsistent evidence. Examples include topical 5% ketamine (negative randomized trial), manual acupuncture (many small trials with high risk of bias and possible publication bias), MIRE (limited low‑quality evidence, no pain relief), and ozone therapy (small RCTs with unclear quality), which are not supported as established therapies based on current data.
Evidence remains insufficient to conclude clinical benefit for ozone therapy in diabetic foot ulcers and for monochromatic infrared phototherapy (MIRE) to treat neuropathic pain; the trials reviewed were small, had methodological limitations, and produced inconsistent or low‑quality results, so these modalities are not established as medically necessary.
Several interventions are described only in preclinical models, small pilot trials, or uncontrolled series and therefore are considered investigational. Autologous bone marrow‑derived stem cell therapies have supportive preclinical rationale and uncontrolled human cohorts but lack randomized controlled trials; dorsal root ganglion (DRG) stimulation evidence is limited to a small retrospective series (n=10); these findings indicate preliminary data rather than definitive efficacy.
Systematic reviews cited in the policy found limited and inconsistent evidence across several modalities. For instance, the MIRE review (6 RCTs, low‑quality evidence) showed only short‑term tactile sensitivity improvement and no pain relief, manual acupuncture systematic review identified many small biased trials preventing firm conclusions, and the ozone Cochrane review (3 small RCTs) could not draw reliable conclusions due to methodological concerns.
Coding and Billing References
| 63650 | Percutaneous implantation of neurostimulator electrode array, epidural. |
| 63655 | Laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural. |
| 63661 | Removal of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy, when performed. |
| 63662 | Removal of spinal neurostimulator electrode plate/paddle(s) placed via laminotomy or laminectomy, including fluoroscopy, when performed. |
| 63663 | Revision including replacement, when performed, of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy, when performed. |
| 63664 | Revision including replacement, when performed, of spinal neurostimulator electrode plate/paddle(s) placed via laminotomy or laminectomy, including fluoroscopy, when performed. |
| 63685 | Insertion or replacement of spinal neurostimulator pulse generator or receiver, direct or inductive coupling. |
| 64555 | Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve). |
| C1767 | Generator, neurostimulator (implantable), nonrechargeable. |
| C1778 | Lead, neurostimulator (implantable). |
| C1787 | Patient programmer, neurostimulator (implantable). |
| C1816 | Receiver and/or transmitter, neurostimulator (implantable). |
| C1820 | Generator, neurostimulator (implantable), non high-frequency with rechargeable battery and charging system. |
| C1822 | Generator, neurostimulator (implantable), high frequency, with rechargeable battery and charging system. |
| L8685 | Implantable neurostimulator pulse generator, single array, rechargeable, includes extension. |
| L8686 | Implantable neurostimulator pulse generator, single array, non-rechargeable, includes extension. |
| L8687 | Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension. |
| L8688 | Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension. |
| 0552T | Low-level laser therapy, dynamic photonic and dynamic thermokinetic energies, provided by a physician or other qualified health care professional [photo-biomodulation]. |
| 38232 | Bone marrow harvesting for transplantation; autologous. |
| 38241 | Hematopoietic progenitor cell (HPC); autologous transplantation. |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care. |
| G0295 | Electromagnetic therapy, to one or more areas, for wound care other than described in G0329 or for other uses. |
| G0329 | Electromagnetic therapy, to one or more areas for chronic stage III and stage IV pressure ulcers and venous stasis ulcers not demonstrating measurable signs of healing after 30 days of conventional care as part of a therapy plan of care. |
| J0135 | Injection, adalimumab, 20 mg. |
| E08.40-E08.49 | Diabetes mellitus due to underlying condition with neurological complications. |
| E09.40-E09.49 | Drug or chemical induced diabetes mellitus with neurological complications. |
| E10.40-E10.49 | Type 1 diabetes mellitus with neurological complications. |
| E11.40-E11.49 | Type 2 diabetes mellitus with neurological complications. |
| E13.40-E13.49 | Other specified diabetes mellitus with neurological complications. |
Provider Actions, Prior Authorization, and Documentation
Prior authorization required for neurostimulator implantation codes
Prior authorization is required for implantation of spinal or peripheral neurostimulator devices. Providers should document that neurostimulator implantation (including CPT codes 63650, 63655, 63685, L8685–L8688 and related implantable device HCPCS/CPT) meets medical necessity criteria and that trial stimulation (when applicable) demonstrated adequate pain relief per policy before permanent implantation.
- Affected codes: CPT 63650, 63655, 63661–63664, 63685, 64555; HCPCS L8680–L8695, C1820/C1822, C1883
- Document trial success: ≥50% pain relief during temporary SCS trial for eligibility for permanent implant (when policy requires)
- Refer to CPB 0194 - Spinal Cord Stimulation for specific eligibility and implantation criteria
Prior authorization recommended for invasive or investigational therapies
Prior authorization is recommended for invasive or experimental therapies and for interventions with limited or preliminary evidence. Providers should obtain authorization and submit complete documentation of prior treatments and objective findings to support medical necessity.
- Examples: autologous bone marrow–derived stem cell transplantation, dorsal root ganglion stimulation, electro-analgesia, novel biologics (e.g., anti-NGF agents)
- Include prior therapies tried and failed, objective pain scores, duration of symptoms, and reasons for considering invasive/experimental therapy
Prior authorization: SCS trial requirement
Prior authorization processes should confirm that a temporary spinal cord stimulation (SCS) trial was performed and documented as successful when required by the policy prior to permanent SCS implantation.
- Documented temporary trial result (percent pain relief and duration)
- Neurological exam findings before and after trial
- Clinical justification if permanent implant performed without a documented successful trial
Prior authorization recommended for experimental/novel therapies
For treatments considered experimental or novel (including many listed under "Experimental and Investigational"), prior authorization is recommended and payers may deny coverage if controlled trial evidence is lacking or if the submission lacks adequate objective documentation.
- If pursuing coverage, provide randomized controlled trial (RCT) evidence when available and complete clinical rationale otherwise
- Absence of RCT evidence for efficacy is a denial risk (see policy background discussion on decompressive surgery and other interventions)
Providers should document diagnosis using ICD-10 codes when billing
When billing for therapies, providers must document the clinical diagnosis using appropriate ICD-10 codes and provide supporting clinical information: diagnostic assessment, prior conservative and pharmacologic therapies tried and failed, pain scores, objective neurological examination findings, and results of any diagnostic tests.
- Include DN4 or other validated pain assessment results when available
- List pharmacologic agents tried (e.g., pregabalin, gabapentin, duloxetine, TCAs, opioids) and response
- For SCS or neurostimulator implants, include trial results, device model, and procedural reports
Percutaneous electrical stimulation medically necessary only after failure of conventional treatments
Percutaneous electrical stimulation is medically necessary only after failure of conventional medical treatments. Use beyond 4 weeks is considered not medically necessary; providers should document prior adequate trials of guideline-recommended pharmacologic therapies and responses.
- Document prior pharmacologic management (e.g., pregabalin, duloxetine, amitriptyline, capsaicin) and why alternatives were ineffective or intolerable
- Duration limit: percutaneous electrical stimulation >4 weeks is considered not medically necessary
Step therapy for pharmacologic management
Step-therapy expectations: document trials of first-line pharmacologic agents before escalating to invasive neuromodulation. If step therapy is bypassed due to intolerance or contraindication, include clear clinical justification in the prior authorization request.
- Typical step sequence: optimized trial of gabapentinoid and at least one other analgesic class with ≥30% pain reduction assessment prior to neuromodulation referral
- If alpha‑lipoic acid (ALA) is used as a supplement, consider it after first-line drugs; document trial and response (UpToDate suggests oral ALA 600 mg daily trial when used)
Step therapy: refractory medical management before SCS
Refractory medical management should be documented prior to SCS consideration. Providers must include pain duration, VAS scores, prior medication trials at therapeutic doses, and reasons for failure or intolerance to conservative measures.
- Document duration of PDN, prior medication classes and doses, VAS or other pain scores, HbA1c and BMI when relevant to SCS eligibility
- Include neurologic exam and monofilament testing results where applicable
Provider action: Absence of well‑designed randomized controlled trials increases denial risk
Absence of well‑designed randomized controlled trials (RCTs) or controlled prospective studies for an intervention increases the risk of noncoverage. Providers should be aware that procedures lacking RCT evidence (for example, decompressive lower‑limb nerve surgery in DSDP per Cochrane review) may not meet medical necessity standards and can be denied without robust supporting data.
- If submitting for therapies with limited evidence, include any available RCTs, high‑quality comparative studies, objective outcome measures, and rationale for why standard options are unsuitable
- Lack of controlled trial evidence is a specific denial risk noted in policy background
Background and Scope
Background: Diabetic neuropathy (DN) denotes neuropathic signs and symptoms occurring in people with diabetes after exclusion of other causes, with distal symmetric polyneuropathy being the most common presentation. Management emphasizes risk‑factor control (including glycemic and cardiovascular risk) and symptomatic pharmacologic treatments for neuropathic pain; surgical decompression is noted as having mixed and largely low‑quality evidence except when used for defined entrapment syndromes.
Definitions and Clinical Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.